Growth Hormone Deficiency
Growth hormone deficiency (GHD) and panhypopituitarism are complex multi-axis endocrine disorders that occur when the pituitary gland is partly or completely damaged (by a pituitary tumor, surgery, radiotherapy, Sheehan syndrome or a congenital defect). An isolated lack of GH, or a combined loss of the anterior pituitary hormones – GH, TSH (thyroid-stimulating hormone), ACTH (adrenocorticotropic hormone), LH/FSH (gonadotropins) and MSH/prolactin – cuts off the hormonal signals that regulate the skin. The skin is a sensitive mirror of this endocrine failure: the dermis thins as GH/IGF-1 is lost, dryness and lipid depletion follow TSH deficiency, the skin becomes thin and bruises easily without ACTH/cortisol, and overall pallor develops as MSH declines. At Haute-Derma, we have developed a specialized medical approach to restore the lipid barrier, stimulate collagen remodeling and bring life back to thin, atrophic skin in patients with pituitary failure.
How hormone loss affects skin cells and metabolism:
- Dermal Atrophy and Poor Regeneration from Loss of GH/IGF-1:
- Without GH, the IGF-1 pathway that stimulates fibroblasts stalls. Fibroblasts divide far less, and production of type I and III collagen and glycosaminoglycans (GAGs) falls sharply.
- Lower GAG levels (especially the body's own hyaluronic acid) reduce the tissue's ability to hold water, so the dermis becomes noticeably thinner, fine wrinkles multiply, elasticity drops and wounds heal slowly.
- Lipid Depletion and Severe Dryness from TSH Deficiency (Secondary Hypothyroidism):
- TSH deficiency causes secondary hypothyroidism, slowing keratinocyte metabolism and shrinking the sebaceous glands.
- Production of the essential barrier lipids (ceramides, free fatty acids, cholesterol) is disrupted, increasing transepidermal water loss (TEWL) and leading to rough, flaky, chronically itchy skin.
- Reduced Pigmentation and Epidermal Thinning from ACTH/MSH and LH/FSH Deficiency:
- A lack of MSH (melanocyte-stimulating hormone) and ACTH lowers tyrosinase activity in melanocytes, leaving the skin pale and lacking its natural glow.
- Falling sex steroid levels (estrogen/testosterone) due to LH/FSH deficiency speed up thinning of both the epidermis and the dermis and reduce microcirculation, so the skin becomes paper-thin and bleeds under the surface with minor knocks.
Skin Signs of GHD and Panhypopituitarism
| Clinical feature | What it looks like | Cellular and molecular mechanism |
|---|---|---|
| Thin, atrophic, prematurely aged skin | Thin, dry skin with many fine wrinkles and loss of subcutaneous fat, most obvious on the face and forearms. | GH/IGF-1 and LH/FSH deficiency reduces collagen I/III and elastin and causes fibroblast atrophy. |
| Severe dryness and scaling (xerosis) | Rough, cracked skin with fine scale, reduced or absent sweating and oil production, causing itching and stinging. | TSH deficiency (secondary hypothyroidism) shrinks sebaceous/sweat glands and reduces barrier ceramide production. |
| Pallor and loss of glow | Pale, dull skin with generalized reduced pigmentation but no localized vitiligo-like patches. | ACTH/MSH deficiency reduces tyrosinase activation; poor microcirculation to the epidermis. |
| Easy bruising and slow wound healing | Bruises and purpura appear after minor trauma; wounds take weeks to close. | Cortisol/GH deficiency weakens vessel walls and reduces new capillary growth for repair. |
| Hair loss and sparse body hair | Dry, sparse scalp hair; axillary, pubic and body hair falls out or fails to develop. | Androgen deficiency (from ACTH and LH/FSH deficiency) causes atrophy of androgen-dependent hair follicles. |
Skin Findings: Panhypopituitarism vs. Primary Adrenal Insufficiency (Addison Disease)
| Feature | Panhypopituitarism | Primary Adrenal Insufficiency (Addison Disease) |
|---|---|---|
| Skin pigmentation (melanogenesis) | Pale skin, reduced pigment from ACTH/MSH deficiency | Darkened skin (hyperpigmentation) from compensatory high ACTH/MSH |
| Typical sites of darkening | No darkening in skin creases, mucosa or new scars | Marked darkening in palmar creases, oral mucosa and over joints |
| Dryness and sebaceous function | Very dry skin (from TSH + GH deficiency) | Moderately dry skin (mainly from fluid and electrolyte loss) |
| Dermal thickness and collagen | Widespread thinning (from GH + sex steroid deficiency) | Moderate skin atrophy |
| Body and scalp hair | Sparse/widespread loss (complete gonadotropin deficiency) | Reduced axillary/pubic hair in women; men little affected |
Our Approach
At Haute-Derma, the diagnostic and dermatologic work-up for patients with GH deficiency and panhypopituitarism follows a comprehensive medical approach:
- Clinical Signs and Medical History:
- A detailed history of head surgery, pituitary radiotherapy, traumatic brain injury or heavy postpartum bleeding (Sheehan syndrome), and symptoms such as fatigue, cold intolerance and low blood pressure.
- Clinical assessment of skin thinning, surface hydration, elasticity and the distribution of hair across the body.
- Endocrine Testing (With the Endocrinology Team):
- Pituitary hormone panel: IGF-1, TSH and free T4, morning cortisol and ACTH, LH, FSH, estradiol/testosterone and prolactin.
- Dynamic stimulation tests (such as the insulin tolerance test, ITT), performed by the endocrinologist to assess GH and ACTH reserve.
- Skin Structure Assessment at Haute-Derma:
- Transepidermal water loss (TEWL): measures how damaged the protective lipid barrier is.
- Dermoscopy and high-frequency ultrasound (HFUS): accurately measure dermal thickness, collagen fiber density and the echogenicity of the dermal matrix.
Treatment Options at Haute-Derma
Alongside systemic hormone replacement, our protocol at Haute-Derma focuses on intensive local nourishment, barrier repair and stimulation of dermal regeneration:
- Coordinated Systemic Hormone Replacement Therapy (HRT): Patients must follow the hormone replacement plan prescribed by their endocrinologist: levothyroxine (for TSH deficiency), hydrocortisone/prednisolone (for ACTH deficiency), sex hormones (estrogen/progesterone or testosterone) and recombinant GH (rhGH) where indicated.
- Barrier Repair and Deep Hydration at Haute-Derma:
- Rebuilding the epidermal lipid layer: Dermocosmetics with an optimized ceramide complex (1:3:1), cholesterol and free fatty acids help bind keratinocytes together, relieve xerosis and lower TEWL.
- Deep hydration: Iontophoresis or molecular electroporation delivers multi-weight hyaluronic acid and panthenol (vitamin B5) deep into the epidermis.
- Rejuvenating and Rebuilding the Thinned Dermis:
- Regenerative micro-injection mesotherapy: Growth peptides (signal peptides, copper tripeptide-1), essential amino acids and polynucleotides (PDRN) are delivered directly into the dermis to activate fibroblasts and boost collagen production, compensating locally for the lack of GH.
- Photobiomodulation: Red LED (630 nm) combined with near-infrared LED (830 nm) increases ATP production in the mitochondria of keratinocytes and fibroblasts and improves the microcirculation that nourishes the skin.
